Onco-Innovations Expands into Australia with New Subsidiary and Partnership

Onco-Innovations Limited announces a strategic expansion into Australia through an engagement agreement with RDI Partners and the formation of Onco-Innovations AU Pty. Ltd. This move aims to strengthen the company's Phase I development activities by leveraging Australia's regulatory and financial benefits, including the 43.5% R&D Tax Incentive program.

The establishment of ONCO AU will support compliance with local regulations and enhance clinical trial capabilities in Australia, a region known for its efficient early-phase clinical trial processes. The partnership with RDI Partners will ensure financial oversight, especially regarding Australian R&D tax incentive eligibility and clinical expenditures.

Additionally, Onco-Innovations has engaged MCS Market Communication Service GmbH for online marketing services, aiming to bolster its presence through digital channels until July 2026. The marketing agreement, valued at EUR 213,000, highlights the company's commitment to expanding its outreach while adhering to strict financial governance.